602 related articles for article (PubMed ID: 28874546)
1. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.
Cohen JD; Javed AA; Thoburn C; Wong F; Tie J; Gibbs P; Schmidt CM; Yip-Schneider MT; Allen PJ; Schattner M; Brand RE; Singhi AD; Petersen GM; Hong SM; Kim SC; Falconi M; Doglioni C; Weiss MJ; Ahuja N; He J; Makary MA; Maitra A; Hanash SM; Dal Molin M; Wang Y; Li L; Ptak J; Dobbyn L; Schaefer J; Silliman N; Popoli M; Goggins MG; Hruban RH; Wolfgang CL; Klein AP; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Lennon AM
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10202-10207. PubMed ID: 28874546
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
[TBL] [Abstract][Full Text] [Related]
3. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
4. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance.
Okada T; Mizukami Y; Ono Y; Sato H; Hayashi A; Kawabata H; Koizumi K; Masuda S; Teshima S; Takahashi K; Katanuma A; Omori Y; Iwano H; Yamada M; Yokochi T; Asahara S; Kawakubo K; Kuwatani M; Sakamoto N; Enomoto K; Goto T; Sasajima J; Fujiya M; Ueda J; Matsumoto S; Taniue K; Sugitani A; Karasaki H; Okumura T
J Gastroenterol; 2020 Dec; 55(12):1183-1193. PubMed ID: 32939577
[TBL] [Abstract][Full Text] [Related]
5. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing.
Macgregor-Das A; Yu J; Tamura K; Abe T; Suenaga M; Shindo K; Borges M; Koi C; Kohi S; Sadakari Y; Dal Molin M; Almario JA; Ford M; Chuidian M; Burkhart R; He J; Hruban RH; Eshleman JR; Klein AP; Wolfgang CL; Canto MI; Goggins M
J Mol Diagn; 2020 Jun; 22(6):748-756. PubMed ID: 32205290
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
[TBL] [Abstract][Full Text] [Related]
7. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?
Liu DSK; Mato Prado M; Giovannetti E; Jiao LR; Krell J; Frampton AE
Expert Rev Mol Diagn; 2019 Jul; 19(7):553-558. PubMed ID: 31159604
[No Abstract] [Full Text] [Related]
8. Perioperative cell-free mutant KRAS dynamics in patients with pancreatic cancer.
Hipp J; Hussung S; Timme-Bronsert S; Boerries M; Biesel E; Fichtner-Feigl S; Fritsch R; Wittel UA
Br J Surg; 2021 Apr; 108(3):239-243. PubMed ID: 33793718
[No Abstract] [Full Text] [Related]
9. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
[TBL] [Abstract][Full Text] [Related]
10. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.
Lee JS; Park SS; Lee YK; Norton JA; Jeffrey SS
Mol Oncol; 2019 Aug; 13(8):1623-1650. PubMed ID: 31243883
[TBL] [Abstract][Full Text] [Related]
11. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR
Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500
[TBL] [Abstract][Full Text] [Related]
13. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project.
Bardol T; Dujon AM; Taly V; Dunyach-Remy C; Lavigne JP; Costa-Silva B; Kurma K; Eslami-S Z; Cayrefourcq L; Canivet C; Muscari F; Bournet B; Alix-Panabières C
BMC Cancer; 2024 Jun; 24(1):709. PubMed ID: 38853244
[TBL] [Abstract][Full Text] [Related]
14. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
[TBL] [Abstract][Full Text] [Related]
17. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
Brychta N; Krahn T; von Ahsen O
Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
[TBL] [Abstract][Full Text] [Related]
18. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
19. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma.
Kriz D; Ansari D; Andersson R
Clin Transl Oncol; 2020 Dec; 22(12):2170-2174. PubMed ID: 32447642
[TBL] [Abstract][Full Text] [Related]
20. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]